Bio-Gene Technology Limited (BGT) Earnings Call Transcripts
Bio-Gene Technology Limited's Latest Earnings Call - June 3, 2026
In the June 2026 earnings call, Bio-Gene Technology Limited (BGT:AU) highlighted significant developments, particularly the upcoming launch of Qcide in Japan and advancements in Flavocide's regulatory pathway. The company reported a capital raise of approximately $3.3 million, which is expected to fund operations through late 2027. Management maintained a positive outlook, signaling that initial revenue from Qcide is anticipated in Q3 2026, with further product launches and regulatory submissions expected in the coming year.
Reported metrics
| Metric | Value |
|---|---|
| Capital Raised | $3.3M (positive) |
| Household Insecticide Market Size (Japan) | $1B (positive) |
| First Revenue from Qcide | Q3 2026 (positive) |
| Flavocide Regulatory Submission | March-April 2027 (positive) |
| Upcoming Study Results | September 2026 (positive) |
Guidance from management
Management expects initial revenue from Qcide in Q3 2026, with a product launch in Japan planned for Q4 2026. The regulatory submission for Flavocide is anticipated in March-April 2027, with ongoing studies providing critical data in the interim.
What management said
Sure. Yes. So as I mentioned earlier, we're obviously working on that at the moment. And as you'd appreciate, there are quite a few elements to that, pricing and supply terms. Basically, we have planned a supply agreement and a commercial license arrangement. And obviously, we're keen to get that finalized, and we'll make an announcement in due course.
Look, I can't really comment on the share price. It's obviously a function of many factors. There's been no additional news flow relating to the business, and it's just -- it's a market dynamic that I can't really comment on.
What analysts pressed on
Analysts expressed concerns regarding the timeline for finalizing the Sumitomo agreement and the potential impact of the recent capital raise on share price. There were inquiries about the licensing structure and market dynamics affecting revenue projections.
Main topics on the call
- Qcide Launch in Japan — Bio-Gene is set to launch Qcide in Japan with Sumitomo Corporation and Nakashima, targeting the household nuisance insect pest market. Initial revenue is expected in Q3 2026, with online sales and further distribution pl...
- Flavocide Regulatory Pathway — The company is progressing towards its first regulatory submission for Flavocide in Australia, anticipated in March-April 2027. Management emphasized the importance of upcoming neurotoxicity and reproductive toxicity stu...
- Capital Raise and Financial Outlook — Bio-Gene successfully raised approximately $3.3 million through a placement and securities purchase plan, which will support operations until late 2027. Management noted, "We see the proceeds taking us through to late ne...
- Market Opportunities — The household insecticide market in Japan is valued at around $1 billion, with the nuisance insect pest category being a significant component. Management highlighted, "It's a large market opportunity for us," indicating...
Read the full Bio-Gene Technology Limited transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Bio-Gene Technology Limited
Bio-Gene Technology Limited (BGT) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on ASX and is based in AU. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 2 calls on record spanning February 4, 2025 to June 3, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 2 Bio-Gene Technology Limited earnings call transcripts on record, spanning February 4, 2025 to June 3, 2026. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.
| Quarter | Date | |
|---|---|---|
| Shareholder/Analyst Calls | Jun 3, 2026 | Read transcript → |
| Special Calls | Feb 4, 2025 | Read transcript → |